Cohen Capital Management Inc. Decreases Stake in Solventum Co. (NYSE:SOLV)

Cohen Capital Management Inc. reduced its position in Solventum Co. (NYSE:SOLV) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,195 shares of the company’s stock after selling 137 shares during the period. Cohen Capital Management Inc.’s holdings in Solventum were worth $740,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Modus Advisors LLC bought a new stake in shares of Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC purchased a new position in Solventum in the 4th quarter valued at approximately $26,000. Crews Bank & Trust bought a new stake in Solventum during the 4th quarter valued at $32,000. True Wealth Design LLC lifted its position in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new position in shares of Solventum in the third quarter worth $35,000.

Solventum Price Performance

Shares of SOLV opened at $73.08 on Friday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm’s 50 day simple moving average is $71.14 and its 200 day simple moving average is $69.15.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of analyst reports. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Mizuho began coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.